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Functioning of proteins efficiently at the solid–liquid
interface is critical to not only biological but also modern
man-made systems such as ELISA, liposomes and bio-
sensors. Anchoring hydrophilic proteins poses a major
challenge in this regard. Lipid modification, N-acyl-S-
diacylglyceryl-Cys, providing an N-terminal hydrophobic
membrane anchor is a viable solution that bacteria have
successfully evolved but remains unexploited. Based on the
current understanding of this ubiquitous and unique bac-
terial lipid modification it is possible to use Escherichia coli,
the popular recombinant protein expression host, for con-
verting a non-lipoprotein to a lipoprotein with a hydro-
phobic anchor at the N-terminal end. We report two
strategies applicable to non-lipoproteins (with or without
signal sequences) employing minimal sequence change.
TakingperiplasmicShigellaapyraseasanexample, its signal
sequence was engineered to include a lipobox, an essential
determinant for lipid modification, or its mature sequence
was fused to the signal sequence of abundant outer
membrane lipoprotein, Lpp. Lipidmodification was proved
by membrane localization, electrophoretic mobility shift
and mass spectrometric analysis. Substrate specificity
and specific activity measurements indicated functional
integrity after modification. In conclusion, a convenient
protein engineering strategy for converting non-lipoprotein
to lipoprotein for commercial application has been devised
and tested successfully.
Keywords: apyrase/bacterial lipid modification/signal
sequence
Introduction
Biological systems and biotechnological applications depend
on amphipathic surface proteins that have to perform effec-
tively and efficiently in the aqueous or solid–aqueous interface,
while firmly anchored to a hydrophobic surface. For example,
nutrient uptake by organisms, signal transduction and response,
growth and development require many types of membrane-
associated proteins. Similarly, man-made applications such
as ELISA and biosensors require a variety of functional pro-
teins immobilized to hydrophobic surfaces such as plastics.
Biological systems have resorted to modifying proteins with
lipids or having hydrophobic transmembrane regions to anchor
such proteins to membranes. Further, attachment of proteins
to membranes has also been shown to reduce diffusion in
three dimensions to two dimensions, resulting in effective
concentration of 1000-fold (Stanley et al., 1998), an impor-
tant factor in initial signal transduction events.
Chemical modification of proteins with lipid was first
attempted for exploiting lipoproteins as superior antigens
owing to the action of lipid as a powerful adjuvant (Cote-Sierra
et al., 2002; Pappalardo, 2003). However, such chemical mod-
ifications suffer from lack of specific, quantitative modification
(Shigematsu et al., 1998). Therefore, a biological alternative is
an attractive proposition owing to the possibility of accurate
and precise site-directed lipid modification. Among different
types of biological lipid modification of proteins, the bacterial
approach is the most suitable for the following reasons. In
all known bacteria, more than 770 reported lipoproteins
(Madan Babu and Sankaran, 2002) with a variety of functions
are attached to the membrane having the same N-acyl-S-
diacylglyceryl-Cys as their N-terminal amino acid (Figure 1)
(Sankaran and Wu, 1994), clearly indicating that a variety of
functional proteins can be lipid modified.
The covalent lipid modification of protein was first demon-
strated in Escherichia coli murein lipoprotein (Braun and
Rehn, 1969) and all three enzymes constituting the pathway
have been identified and even partly characterized (Sankaran
and Wu, 1994). The consensus amino acids sequence
[LVI][ASTVI][GAS] C for lipid modification is present in
the C-region of the signal sequence (Hayashi and Wu, 1990).
Bacterial lipoproteins are synthesized as precursors containing
a tripartite signal sequence. The N-region contains 5–7 residues
with two positively charged Lys or Arg residues. The
uncharged hydrophobic region contains 7–22 residues, with
a modal value of 12 residues. These features are common
even to other non-lipoproteins that cross the inner membrane.
The distinguishing feature between the two is the C-region,
which has a consensus sequence of [LVI][ASTVI][GAS] C,
C being the lipid-modified Cys, the first amino acid in
all bacterial lipoproteins (Von Heijne, 1983; Gennity et al.,
1990; Madan Babu and Sankaran, 2002). The first enzyme of
Fig. 1. Structure of N-acyl-S-diacylglycerylcysteine. The diacylglyceryl
moiety is attached to the cysteine SH group by a thioether linkage and the
amino group is fatty acylated. R1 and R3 are palmitoyl residues. R2 can be
either a palmitoyl or an oleoyl residue. This lipid moiety anchors lipoproteins to
membranes.
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the biosynthetic pathway, diacylglyceryl transferase (lgt),
recognizes the consensus sequence at the C-region.
In the absence of a complete understanding of all the deter-
minants needed for bacterial lipid modification, fusion with
prototype lipoproteins was used as a standard strategy for
imparting lipoprotein character to target proteins. The lpp–
OmpA (amino acids 46–159)–PhoA and lpp–OmpA (46–
159)–Bla triple fusions were expressed on an E.coli cell surface
(Georgiou et al., 1996; Stathopoulos et al., 1996) as a means to
achieve surface expression of soluble proteins. Staphylococcus
aureus protein-A, whose beta domain was fused with the signal
sequence, and nine N-terminal amino acid residues of mature
sequence of lpp, incorporated stably into proteoliposome
and was shown to exhibit higher IgG binding activity than
the non-lipoprotein counterpart (Shigematsu et al., 1998).
Leishmanial antigen gp63, fused to OprI lipoprotein of
Pseudomonas aeruginosa, was found to elicit a better immune
response than native gp63 (Cote-Sierra et al., 2002).
In triple fusions, the adverse effect on folding of the target
protein and E.coli outer membrane integrity were highlighted
while expressing such fused proteins (Georgiou et al., 1996;
Stathopoulos et al., 1996). It is absolutely essential in protein
engineering to restrict structural alterations to the minimum by
avoiding unnecessary fusions for applications such as biosen-
sors, ELISA, liposomal integration and enhanced antigenicity.
Moreover, there is no report on systematic studies evaluating
the effect of lipid modification on the folding and functioning
of sensitive molecules such as enzymes. Therefore, it is worth-
while to develop enzymatic reporter lipoprotein with minimum
alterations to study structure–function aspects and convert non-
lipoproteins into lipoprotein form without fusion.
An easily assayable Shigella apyrase (NA) that acts on both
organic and inorganic pyrophosphates to release phosphate
(Bhargava et al., 1995) was chosen as a model protein for
lipid modification. Based on the current knowledge and recent
analysis of structural determinants for lipid modification, two
strategies were designed without any significant fusion or
alteration of sequence in the final product. In the first strategy,
the periplasmic signal sequence of apyrase was modified at the
C-region with consensus sequence for lipid modification. In the
second strategy, the outer membrane Braun’s lipoprotein (lpp)
signal sequence was fused with the apyrase mature sequence.
Both the modified apyrase inserts were ligated into pRSET-B
vector, expressed in E.coli GJ1158 and characterized.
Materials and methods
Bacterial strains, growth conditions and plasmid
The expression host E.coli BL21 (DE3) and plasmid mainte-
nance host E.coli DH5a were obtained from Invitrogen.
Escherichia coli BL21 (DE3) has T7 RNA polymerase gene
under the control of IPTG inducible lac promoter in chromo-
somal DNA. Another commercially available expression host,
E.coliGJ1158, has T7 RNA polymerase gene under the control
of salt inducible proU promoter in chromosomal DNA. Sodium
chloride being inexpensive, the large-scale production of engi-
neered lipoprotein using E.coli GJ1158 will be cost-effective
(Poonam Bhandari and Gowri Shankar, 1997).
Native apyrase gene originally in clone pARC251 was sub-
cloned into plasmid pSK, purchased from Stratagene. The
PvuII–HindIII 0.9 kb fragment (Bhargava et al., 1995) served as
the template for amplification of native apyrase and the 738 bp
NdeI–HindIII fragment containing only apyrase ORF cloned
into pRSETB (Invitrogen) served as a template for engineering
lipid modification forms (see below). The gene of Braun’s
lipoprotein (lpp), an abundant prototype outer membrane
murein-bound lipoprotein, was obtained from the plasmid
pKEN111 (Zwiebel et al., 1981).
Escherichia coli BL21 (DE3) and E.coli DH5a as host were
grown at 37C in Luria Bertani (LB) medium and their recom-
binants were grown in the presence of 100 mg/ml of ampicillin.
Escherichia coli GJ1158 was grown in LB medium without
NaCl and its recombinant was grown in the presence of
100 mg/ml of ampicillin.
Lipid modification strategy
Strategy I. As depicted in Figure 2, the signal sequence of
apyrase (residues 1–19) was amplified by PCR using forward
primer (apy-1, 50GGGAATTCCATATGAAAACCAAAAA30)
with restriction site NdeI and reverse primer (apy-2,
50CGCGGATCCACAACCAGCCAGGGGGATAAAAATC-
ATATTTG30) containing sequences for introducing lipobox
and BamHI site that codes for Gly and Ser. Mature sequence
of apyrase (residues 24–246) was amplified by forward primer
(apy-3) with BamHI site (50CGCGGATCCCTGAAGGC-
AGAAGGTTTTC30) and reverse primer (apy-4) with HindIII
site (50CCCAAGCTTTTATGGGGTCAGTTCATT30). The
PCR products of the engineered signal sequence and mature
apyrase sequences were restricted with BamHI followed by
ligation. The gene for LMA1 was then amplified with forward
primer, apy1 and reverse primer, apy4. Amplified LMA1 gene
and pRSET-B vector were restricted with NdeI andHindIII and
ligated (Figure 2) to yield recombinant plasmid pLMA1.
Strategy II. Braun’s lipoprotein signal sequence containing
lipobox and the next residue Ser (residues 1–22) and two addi-
tional amino acids Gly and Ser due to the BamHI site in the
gene was amplified from lpp by PCR using forward primer
(apy-5) with NdeI site (50GGGAATTCCATATGAAAGCT-
ACTAAACTG30) and reverse primer (apy-6) containing
BamHI site (50CGCGGATCCGGAGCAACCTGCCAG30).
Apyrase mature sequence (residues 24–246) was amplified
as described in strategy I and ligated to lpp signal sequence.
LMAII gene was again amplified using forward primer (apy-5)
of lpp signal sequence and reverse primer (apy-4) of mature
apyrase sequence. Amplified LMA II sequence and pRSET-B
vector were restricted with NdeI andHindIII and ligated to give
pLMAII plasmid (Figure 2). All constructs were sequenced
using an Applied Biosystems 310 DNA sequencer to confirm
their sequence.
Whole-cell assay for apyrase expression and screening
for consistent hyper producer
Apyrase clones were screened for expression by simple colori-
metric assay (Madan Babu et al., 2002). At 0.6 OD600 nm, E.coli
BL21 (DE3) clones were induced with 1 mM IPTG and E.coli
GJ1158 clones were induced with 0.3 M NaCl for 3 h at 37C.
A 1 ml volume of induced cultures was spun down and the cells
were washed three times with 0.9% saline, suspended in 500 ml
of Tris (50 mM)–EDTA (10 mM), pH 7.5 (TE), and left on ice
for 20 min; 20 ml aliquots were added to TE containing ATP to
give a final assay volume of 150 ml and a final ATP concen-
tration of 5 mM. After 15 min of incubation at 37C, cells were
pelleted using a microfuge, the supernatant was transferred to a
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microplate well and 100 ml of Chen’s reagent were added. After
15 min at room temperature, the absorbance was measured at
650 nm in a microplate reader and the amount of phosphate
released was read from a phosphate calibration graph.
Routinely after every transformation, 20 colonies were ran-
domly selected and screened by the above method to choose
hyper-expressing clones. Normally we obtained 4–5 hyper-
expressing clones. These were plated for single colonies
and, from each set, five colonies were selected and assayed
again. Only those which were consistently over-producing
(activity in 1 ml of 1 O.D. culture >0.5 mmol/min) were
retained as stable hyper-expressing clones. Glycerol stocks
were prepared and frozen at 80C for storage. Stab cultures
were prepared and stored at 4C. Hyper-expressing clones were
confirmed by PCR for apyrase insert.
Cell fractionation
Volumes of 50 ml of induced native and lipid modified apyrase
cultures were pelleted at 2500 g for 10 min at 4C. The pellets
were washed three times with 0.9% saline and suspended in
5 ml of TE containing 20% sucrose, 100 mg of lysozyme/ml
final, pH 7.5. The cell suspensions were incubated for 20 min at
room temperature and pelleted at 1000 g for 15 min at 4C.
The supernatant was used as the periplasmic fraction and stored
at20C for further use. The pellets were suspended in 5 ml of
TE. The cells were lysed using a French press at 16 000 psi and
centrifuged at 2500 g for 10 min at 4C to remove debris.
Supernatants were centrifuged at 200 000 g for 30 min at
4C to pellet total membrane, which was then suspended in
500 ml of 1% sodium lauryl sarcosine (which gives a detergent
to protein ratio of 5) and incubated for 1 h on ice for solu-
bilization (Filip et al., 1973).
The sample was centrifuged at 200 000 g for 45 min at 4C.
Sarcosyl-solubilized supernatant was retained as the inner
membrane fraction and stored at 20C. The pellet,
sarcosyl-insoluble portion, was suspended in 500 ml of TE
and used as the outer membrane fraction. Apyrase activity
was assayed in these fractions essentially as described above
except that the assay was conducted in microplate wells with
appropriate dilutions of the enzyme source added in place
of cells.
Purification of apyrases by electroelution
Total protein amounting to 5 mg from each of inner membrane
preparations of LMA-I, LMA-II and periplasmic fractions of
native apyrase were resolved separately using 12% preparative
SDS–PAGE. The gels were immersed in 1 M ice-cold KCl for
15 min. Owing to over-expression apyrases appeared as thick,
Fig. 2. Cloning strategies for lipid modification of apyrase. LMA-I: four amino acid residues at the C-terminal end of the apyrase signal sequence were replaced by a
lipobox sequence (LAGC) by PCR and ligated with apyrase mature sequence (see Materials and methods, Strategy I, for details). LMA-II: Braun’s lipoprotein signal
sequence is fused with apyrase mature sequence (seeMaterials and methods, Strategy II, for details). LMA-I and LMA-II inserts were ligated to pRSET-B vector and
the two recombinant plasmids pLMAI and pLMAII were expressed in E.coli BL21 (IPTG induction) and in E.coli GJ1158 (salt induction).
Bacterial lipid modification of proteins
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white bands, whose middle portion was easily excised from
the gel. Following soaking of the gel pieces in 1 M NaCl for
15 min and then washing in water, apyrases were electroeluted
in 25 mM Tris, 190 mM glycine, pH 8.9 at 100 mA for 3 h
(Bhargava et al., 1995). The purity and molecular weight of the
electroeluted samples were confirmed in 12% SDS–PAGE
stained with Coomassie Brilliant Blue R-250 and also tricine
SDS–PAGE (see below). The protein concentrations were
measured by Lowry’s method (Lowry et al., 1951).
Mobility shift in tricine SDS–PAGE
Tricine SDS–PAGE has been regularly used in the demonstra-
tion of mobility shift after bacterial lipid modification, espe-
cially in case of Braun’s lipoprotein (Schlesinger, 1993). In
fact, this method has been successfully used to identify the
intermediates during in vivo and in vitro lipid modification
(Ichihara et al., 1981). Therefore, it was used as first-line evi-
dence of lipid modification of apyrase and also to establish the
homogeneity of the preparations by electroelution. Samples of
5 mg of purified native and lipid-modified apyrases, as esti-
mated by Lowry’s method, were loaded on to 15% tricine
SDS–PAGE gel. Tricine SDS–PAGE (15% T, 6% C gel and
18 h run at 100 V) was performed as described previously
(Strom et al., 1993) and protein was stained with Coomassie
Brilliant Blue R-250.
Matrix-assisted laser desorption/ionization time-of-flight
(MALDI-TOF) mass spectrometry
Protein bands (NA, LMA-I and LMA-II) were excised from
Coomassie Brilliant Blue G-250-stained 12% SDS–PAGE gel
and washed three times in 1 ml of 50% acetonitrile containing
25 mM ammonium bicarbonate pH 8.0 for 30 min. The gel
pieces were soaked in acetonitrile for 5 min. Acetonitrile was
aspirated out and the gel pieces were dried in a Speed-Vac and
re-swollen in 6 ml of 25 mM ammonium bicarbonate pH 8
containing 15 ng/ml of TPCK-treated Trypsin (Sigma). The
swollen gel pieces were incubated overnight at 37C. The
gel slices were soaked in 100 ml of 50% acetonitrile containing
5% trifluoroacetic acid for 1 h to extract the peptides. The
extraction was repeated and the two extracts were pooled
and dried completely. The dried samples were dissolved
in 6 ml of 50% acetonitrile containing 0.1% trifluoroacetic
acid. The tryptic digests of the protein were analyzed
using a-cyano-4-hydroxycinnamic acid (HCCA) or 2,5-
dihydroxybenzoic acid (DHB) as matrix. In a modification
for lipopeptides, 2 ml of sample were mixed with 2 ml of
octyl glucoside (OG) (1% w/v) in 50% acetonitrile containing
0.1% trifluoroacetic acid. A 1 ml volume of sample was mixed
with matrix solution (3-hydroxybenzoic acid 10 mg/ml in 50%
acetonitrile containing 0.1% trifluoroacetic acid) on a MALDI
target plate. MALDI-TOF mass spectra were acquired using a
PerSeptive Biosystems Voyager-DE STR Biospectrometry
workstation.
The mass spectrometer is fitted with a nitrogen laser that
operates at 337 nm for ionizing the samples. The spectra were
recorded in reflectron mode with delayed extraction in the
positive ion mode. The accelerating voltage was set at
20 kV, the grid voltage at 72% and the delayed extraction
was varied between 160 and 230 ns. The laser intensity was
adjusted to obtain optimal signals and spectra were accumu-
lated from 100 shots in the mass rangem/z 800–4000. The mass
accuracies using the calibrating peptides were 100 p.p.m. The
mass spectra were processed using Data Explorer software
supplied by the manufacturer and the list of monoisotopic
peaks was also verified from the spectra manually. The proteins
were identified by using MALDI fingerprint datasets with
Mascot as described earlier (Chamrad et al., 2004). The search
parameters used were partial methionine oxidation, allowed up
to two missed cleavages for trypsin, by selecting NCBI
database and taxonomy Eubacteria. With these experimental
conditions, the tryptic digest of apyrase is expected to give 58
peptides excluding the N-terminal peptide. The N-terminal
peptide could be identified only by using DHB as matrix
along with OG. Detection of lipid-modified peptides by
MALDI mass spectrometry will be considered in detail in
another study. External calibration of spectra was effected
using standard peptides des-Arg0-bradykinin, angiotensin,
Glu0-fibrinopeptide-B and neurotensin (Gharahdaghi et al.,
1999).
Comparison of specific activities of native
and lipid-modified apyrases
Five units (1 unit is defined as the amount of enzyme required
to release 1 mmol of phosphate per minute) each of native
(periplasmic) and lipid-modified apyrases (inner membrane)
and known concentrations of standard proteins were separated
by 12% SDS–PAGE. The gel was stained with Coomassie
Brilliant Blue G-250 and destained thoroughly. The protein
bands corresponding to apyrases were cut from the gel and
dye was eluted with 200 ml of 50% acetonitrile containing
25 mM ammonium bicarbonate. The blue color was read at
650 nm. The amount of native and lipid-modified apyrase was
determined by comparison with the standard protein marker
trypsin loaded alongside.
Haloperoxidase, peroxidase and catalase activities
Shigella apyrase is a member of the bacterial acid phosphatases
and resembles very closely in sequence and 3D structure
E.blattae acid phosphatase. Bacterial acid phosphatases,
apart from phosphatase activity, exhibit haloperoxidase activ-
ity. Therefore, phosphatase, chloroperoxidase, peroxidase and
catalase activities for native and lipid-modified apyrase were
assayed as reported previously (Madan Babu et al., 2002).
Results
Twin strategies for engineering lipid modification
In the first strategy (lipid-modified apyrase-I, LMA-I), the
Shigella apyrase signal sequence was modified using PCR
to include a typical lipobox sequence, –LAGC–, seen in
about 75% of bacterial lipoproteins (Von Heijne, 1983;
Gennity et al., 1990) and two extra amino acids G and S
were introduced after the cysteine because of the BamHI site.
In the second strategy, Braun lipoprotein’s signal sequence
(containing lipobox: LAGC) was directly fused to a mature
sequence of apyrase, with an extra three new amino acids, S, G
and S, following the C in the lipobox. As Shigella apyrase’s
N-terminus is an extended coil in the predicted 3D structure
having no significant role in structure–function relationships
(Madan Babu and Sankaran, 2002), these extra amino acids at
the N-terminal end were presumed not to affect the activity.
On the other hand, they could be useful in probing the role of
the mature sequence adjacent to N-terminal Cys in lipoprotein
targeting.
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Expression of engineered lipoproteins in E.coli hosts
Apyrases, both native and lipid-modified, were expressed in
both E.coli BL21 (DE3) and E.coli GJ1158. As can be seen
from Table I, which contains data from a representative set, the
expression was greater in E.coli BL21 (DE3) than in E.coli
GJ1158. Even in the case of native apyrase the expression in
E.coli GJ1158 was only 75% compared with E.coli BL21
(DE3). LMA-I and -II were expressed to the extent of 64
and 69%, respectively, compared with E.coli BL21 (DE3).
However, a noteworthy observation was the lack of stable
and consistent expression in E.coli BL21 (DE3). When
screened after 7 days, one or two out of 10 colonies from
E.coli BL21 (DE3) but nine out of 10 colonies from E.coli
GJ1158 consistently over-expressed apyrase. Therefore, based
on consistency, apyrase was expressed in E.coli GJ1158 for
further experimentation.
Both LMA-I and LMA-II constructs resulted in similar
expression levels in both E.coli expression systems (salt and
IPTG inducible), but distinctly lower than that of native apyr-
ase. This may perhaps be due to additional processing of lipo-
proteins through lipoprotein biosynthetic machinery even
though both lipoproteins and non-lipoproteins share the
same Sec machinery for transport. The salt inducible expres-
sion was lower by 30% for native and lipid-modified apyrases,
indicating that the lower expression in E.coli GJ1158 was
nothing to do with lipid modification. The reasons for instabil-
ity in E.coli BL21 (DE3) upon storage are not clear.
Membrane localization of periplasmic apyrase
after lipid modification
Lipoproteins are generally membrane bound, either to inner or
outer membrane, normally requiring detergents to solubilize
them. So far no predictive rule for targeting has been formu-
lated for want of a clear understanding of the signals and
factors involved. Therefore, the apyrase activity of native
and lipid-modified forms was assayed in the periplasm, cyto-
plasm, inner membrane and outer membrane fractions of E.coli
GJ1158 clones. As can be seen from Table II, native apyrase
was specifically localized to the periplasm; a small amount
(<10%) of cytoplasmic activity could presumably be due to
contamination by the periplasmic fraction. In contrast, lipid-
modified apyrases (LMA-I and -II) are localized to the
sarcosyl-soluble membrane fraction normally considered to
be inner membrane fraction (Filip et al., 1973).
Since it is possible that apparently the same activity could
have resulted from fortuitous combinations of expression
levels and specific activities, SDS–PAGE was performed to
locate the protein in various fractions and correlate expression
levels with activity. It should be clear from Figure 3A, in
LMA-1 and -II (lanes 5 and 6), only inner membrane fractions
contained lipid-modified forms as bands with comparable
intensity at 25 kDa.
Functional Shigella apyrase has been purified to apparent
homogeneity by electroelution from sarcosyl gels (Bhargava
et al., 1995). In this study, we electroeluted the native and
lipid-modified apyrases in periplasmic and membrane fractions
respectively from SDS–PAGE after cold KCl staining. Sub-
sequent SDS–PAGE showed a single band for lipid-modified
apyrases migrating along with pure native apyrase (data not
shown). The apparent homogeneity can be seen in tricine SDS–
PAGE also (see below).
Demonstration of lipid modification by mobility shift in
tricine SDS–PAGE and mass spectrometric analysis
Tricine SDS–PAGE has been shown to differentiate between
lipid-modified forms of bacterial lipoproteins and it has in fact
Table I. Whole-cell apyrase activity (mmol/min) corresponding to 1 ml of
1 O.D. culture
Protein E.coli
BL21DE3
E.coli
GJ1158
NA 1.30 0.94
LMA-I 0.83 0.53
LMA-II 0.91 0.64
Vector control NDa ND
aND, not detectable.
Table II. Activity (mmol/min) in whole cell and corresponding fractions
from 1 ml of 1 O.D. culture
Clone Whole
cell
Cytoplasm Periplasm Total
membrane
Inner
membrane
Outer
membrane
NA 0.89 0.07 0.87 NDa ND ND
LMA-I 0.51 ND ND 0.53 0.49 ND
LMA-II 0.61 ND ND 0.62 0.57 ND
Vector
control
ND ND ND ND ND ND
aND, not detectable.
Fig. 3. (A) Localization of apyrase in the membrane fraction by SDS–PAGE.
Equal amounts, 100 mg, of total protein from different fractions were loaded on
to SDS–PAGE gel. Lane 1, NA whole cell lysate; lanes 2, 3 and 4, cytoplasmic
fraction of NA, LMA-I and LMA-II, respectively; lanes 5, 6 and 7, inner
membrane fraction of LMA-I, LMA-II and NA, respectively; lanes 8, 9 and
10, outer membrane fraction of LMA-I, LMA-II and NA, respectively. Lipid-
modified apyrases LMA-I and -II are seen at 25 kDa in the inner membrane
fraction only (lanes 5 and 6). (B) Mobility shift of lipid-modified apyrase in
tricine SDS–PAGE. Both LMA-I and LMA-II (lanes 2 and 3) show identical
mobility and move more slowly than the native apyrase (lane 1). When native
apyrase was mixed with LMA-I and -II and ran separately in lanes 4 and 5,
respectively, a doublet was formed corresponding to their individual mobility
(lanes 1, 2 and 3).
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been routinely used to identify partially modified forms of
Braun’s lipoprotein in gel-based assays for biosynthetic
enzymes (Schlesinger, 1993; Sankaran and Wu, 1994). There-
fore, as a first level of indication of bacterial lipid modification,
it was exploited to differentiate the lipid-modified and native
apyrases by virtue of their mobility shift. As expected, lipid-
modified apyrases moved more slowly than native apyrase
(Figure 3B). The doublet in lanes 4 and 5, corresponding to
native and lipid-modified apyrases, ruled out electrophoretic
artifacts.
Although the first-level of evidence from the membrane
localization and mobility shift in tricine SDS–PAGE indicated
that our products were perhaps lipid modified, it is possible that
the signal sequences were not recognized properly by both
lipoprotein and non-lipoprotein signal peptidases and therefore
they were localized in the membrane and moved as higher
molecular weight forms. To prove the point conclusively,
we resorted to mass analysis of the N-terminal fragment.
Mass/charge analysis of tryptic digests of native and lipid
modified apyrases (LMA-I, LMA-II) by MALDI-TOF mass
spectrometry was performed using an improvised method
described in the methodology. Previously mass spectrometric
analysis was used to demonstrate lipid modification of surface
lipoprotein from S.pneumoniae and outer membrane lipopro-
teins MlpA from P.multocida (Cullen et al., 2003).
The tryptic digest of LMA-I in addition to other peaks
showed peaks at m/z 1321.7902 and 1295.7786 that
corresponded to N-terminal lipidated peptides N-palmitoyl-
S-(1-palmitoyl-2-oleoyl)glyceryl-Cys-Gly-Ser-Leu-Lys and
N-palmitoyl-S-(1,2-dipalmitoyl)glyceryl-Cys-Gly-Ser-Leu-Lys,
respectively. LMA-II showed a peak at m/z 1409.7545 that
corresponded to its N-terminal lipidated peptide, N-palmitoyl-
S-1-palmitoyl-2-oleoylglyceryl-Cys-Ser-Gly-Ser-Leu-Lys
(Figure 4A and B). Owing to the high resolving power, isotopic
resolution of the molecular ions is observed. These m/z values
determined by mass spectrometry are in good agreement with
the theoretically calculated m/z values of N-terminal lipidated
peptides. Native apyrase, which was used as a control, did not
show a peak that corresponded to the m/z of N-terminal
lipidated peptides. When a list of peptide monoisotopic
peaks arising from tryptic digests of lipid modified apyrase
was submitted to Mascot (http://www.matrixscience.com) by
selecting NCBI database and taxonomy Eubacteria for a simi-
larity search, it showed similarity with Shigella flexneri apyrase
with acceptable scores, which is significant for identification of
the protein (Table IV). This confirms that the N-terminus of
apyrase is lipid modified in the same way as normal bacterial
lipoproteins (Gharahdaghi et al., 1999; Cullen et al., 2003).
The mass spectral analysis revealed another established fact
characteristic of lipoproteins. The lipid acyl composition of
diacylglyceryl group (Figure 1) is actually the same as that
of phospholipids, especially its donor phosphatidylglycerol.
Although the relative proportions could vary depending on
the growth stage and metabolic status, R1 is always palmitate
and R2 can be oleoyl or palmitoyl, the former being predomi-
nant (Cronan and Gelmann, 1975; Raetz, 1978, 1982;
Schlesinger, 1993). LMA-I showed peaks at m/z 1321.7902
and 1295.7786, matching the peaks predicted based on oleoyl
(predicted mass 1321.97) or palmitoyl residues (predicted mass
1295.94) at the second position. The peak for LMA-II is at m/z
1409.7545, corresponding to the oleoyl form (predicted mass
1409.06).
Fig. 4. (A)Mass spectrumofLMA-I. Twopeaks shownby arrowswithm/z 1321.7902 and 1295.7786 indicate themonoisotopicmass ofN-palmitoyl-S-(1-palmitoyl-
2-oleoyl)glyceryl-Cys-Gly-Ser-Leu-Lys and N-palmitoyl-S-(1,2-dipalmitoyl)glyceryl-Cys-Gly-Ser-Leu-Lys, respectively. (B) Mass spectrum of LMA-II. A single
peak shown by an arrow with m/z value of 1409.7545 indicates the monoisotopic mass of N-palmitoyl-S-(1-palmitoyl-2-oleoyl)glyceryl-Cys-Ser-Gly-Ser-Leu-Lys.
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Demonstration of functional integrity of
lipid-modified apyrases
All previous attempts tomodify non-lipoproteins to lipoproteins
addressed themechanismof lipidmodification for increasing the
antigenicity, owing to the lipid acting as an adjuvant (Zwiebel
et al., 1981; Cote-Sierra et al., 2002). However, the major
concern in protein engineering is that the modification should
not adversely affect the functional properties of the proteins to
be modified. No workers, to the best of our knowledge, have
deliberately looked into this aspect, even though it is known
that lipoproteins come in a variety of structures and functions.
Therefore, we employed an easily assayable heterologous
non-lipoprotein enzyme with good turnover number (reported
kcat = 420) as a reporter lipoprotein (Bhargava et al., 1995).
Apyrase structure has been predicted to have a major a-helical
structure and rather flexible backbone giving rise to a variety of
related activities; a number of known enzymatic variants under
the super-family of bacterial acid phosphatases are known. We
surmised that theN-terminalmodification should not perturb the
enzymeand, if it did, thenweshouldbeable tomonitor it not only
through loss of its activitybut also in the alterationof its substrate
specificity. The variation from phosphatase and haloperoxidase
activities to pyrophosphatase activity seems to be subtle, as the
active site residues are identical and the active site conformation
is apparently the same.
The specific activity of an enzyme is a sensitive measure of
integrity and proper folding of the protein to attain functional
conformation. As can be seen from Table III, the specific
activity of LMA-I and LMA-II remains essentially the same
as that of native apyrase. As expected, there was no variation in
specific activity after bacterial lipid modification. Apyrase does
not possess any significant phosphatase or chloroperoxidase
activity and therefore it has been proposed to form a new
member of the bacterial acid phosphatase family. Our assays
for chloroperoxidase, peroxidase, catalase and phosphatase
were negative and the pyrophosphatase activity of lipid-
modified forms matched that of native apyrase as reported
previously (Madan Babu and Sankaran, 2002).
Discussion
Although bacterial lipoproteins originally contain respective
signal sequences with appropriate structural attributes for
lipid modification, prospective candidates for engineered
lipid modification can come with or without their own signal
sequences, depending on whether they are cytoplasmic or
secretory proteins. Therefore, the applicability of different
strategies for these proteins, the former requiring fusion of a
typical lipoprotein signal sequence and the latter requiring
mere modification of the signal sequence to contain predicted
attributes for lipoprotein, was tested in this study. Since using
the same protein for both the strategies makes better sense for
comparison and evaluation, Shigella apyrase, a periplasmic
protein from another organism, was engineered using either
site-directed mutagenesis of residues at the C-terminal end of
the original signal sequence of apyrase to introduce the typical
lipobox (–LAGC–) present in about 75% of the lipoproteins
(Von Heijne, 1983; Gennity et al., 1990) or fusion of the signal
sequence of the abundant outer membrane lipoprotein, Lpp
(Braun and Rehn, 1969), to the apyrase mature sequence.
The fact that both led to bacterial lipid modification of this
heterologous protein and anchored this periplasmic enzyme to
the membrane suggests that both the strategies work well for
this type of protein engineering and therefore its general applic-
ability to a variety of proteins. Previously the beta domain of
Staph-A protein, alkaline phosphatase and b-lactamase were
lipid modified and expressed as the final fusion product
(Stathopoulos et al., 1996). The fused part may alter the
structure and function of a target protein. In the developed
strategies, modified or fused signal peptide is cleaved off
by signal peptidase-II and finally lipoprotein is expressed
without fusion.
The membrane localization of both LMA-I and LMA-II
indicated that all the attributes and signals necessary for
lipid modification can be adequately provided in the signal
sequence according to the predicted generalization (Von
Heijne, 1983; Gennity et al., 1990; Madan Babu and Sankaran,
2002). Moreover, comparable levels of both modified proteins
(even though LMA-II actually contained the intact signal
sequence of the most abundant Braun’s lipoprotein in the
cell) indicate that the signal sequence does not significantly
influence the levels of expression, at least as long as the same
lipobox, –LAGC–, is used. In bacteria it is known that lipo-
proteins with the same lipobox could be expressed to varying
extents. Therefore, the necessary post-translational attributes
such as recognition by the biosynthetic machinery, especially
the first enzyme, catalyzing the committed step, for maximum
expression of these lipoproteins and the roles of different lipo-
boxes will be an interesting study. In this context, this engi-
neered lipoprotein reporter enzyme will be of great help in
identifying such factors, which have not been adequately
probed into.
The indication for lipid modification was apparent from the
retardation normally seen for lipoproteins and their biosyn-
thetic intermediates in tricine SDS–PAGE. Mass spectrometry
was used to establish lipid modification conclusively by ana-
lyzing the tryptic fragments of native and lipid-modified apyr-
ase molecules. The mass derived from the spectral data could
be accounted for only by assuming lipid modification and not
by fragmentation of unmodified signal peptide as LMA-I and
LMA-II had entirely different signal peptide sequences and the
mass would be much higher than that observed for the lipopep-
tide fragment.
The mass spectrometric analysis revealed another
established fact characteristic of lipoproteins. The lipid acyl
Table III. Comparison among specific activities of native and
lipid-modified apyrases
Clone Units
(mmol/min)
Amount
(mg)
Specific activity
(units/mg)
NA 5 0.014 357
LMA-I 5 0.015 333
LMA-II 5 0.013 385
Table IV. Analysis of m/z of peptides by Mascot software
Protein
sample
Score No. of peptides
matched
Sequence
coverage (%)
NA 97 11 43
LMA-I 49 4 9
LMA-II 109 10 44
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composition of the diacylglyceryl group (Figure 1) is actually
the same as that of phospholipids, especially its donor phos-
phatidylglycerol. Although the relative proportions could vary
depending on the growth stage and metabolic status, R1 is
always palmitate and R2 can be oleoyl or palmitoyl, the former
being predominant (Cronan and Gelmann, 1975; Raetz, 1978,
1982; Schlesinger, 1993). LMA-I showed peaks at m/z
1321.7902 and 1295.7786, matching with peaks predicted
based on oleoyl or palmitoyl residues at the second position.
The peak for LMA-II is at m/z 1409.7545, corresponding to the
oleoyl form.
This observation further confirms that the engineered lipo-
protein signal sequences have been properly recognized and
modified in the same way as that of a typical lipoprotein by the
lipid modification pathway enzymes, namely diacylglyceryl
transferase (lgt), signal peptidase II and N-acyl transferase
(Sankaran and Wu, 1994).
Recently, the sorting of lipoproteins to inner or outer mem-
brane has been studied in some detail and it was shown to
depend on amino acid residues at position 2 and 3, especially
in its role to associate lipoprotein with lipoprotein outer mem-
brane localization complex (Lol CDE) in the inner membrane.
The Lol CDE complex in the inner membrane releases outer
membrane-directed lipoproteins from the inner membrane in
an ATP-dependent manner (Yakushi et al., 2000; Narita et al.,
2002), leading to the formation of a lipoprotein–Lol A complex
in the periplasm (Matsuyama et al., 1995; Tajima et al., 1998).
This complex then interacts with outer membrane receptor
Lol B, which anchors lipoproteins to the outer membrane
(Matsuyama et al., 1997; Tanaka et al., 2001). The strong inner
membrane retention or Lol CDE avoidance function occurs
with Asp at position 2 (Masuda et al., 2002) and Asp, Glu,
Gln or Asn at position 3 (Hara et al., 2003). His, Lys, Val, Ile,
Ala, Cys or Thr at position 3 significantly decreases the inner
membrane retention or Lol CDE avoidance functions of Asp at
position 2 (Hara et al., 2003). It was reported that the distance
between Ca of the main chain and the negative charge of the
side chain makes only Asp suitable for this retention function.
Lipoproteins, LMA-I and LMA-II, have either Gly or Ser at
position 2, respectively (Figure 2), but still retained in the inner
membrane. This indicates that these small and uncharged
amino acids also help in inner membrane retention by prevent-
ing complex formation with Lol CDE. In fact, LMA-II has Ser
of Lpp, the major outer membrane lipoprotein, and it can be
considered for all practical purposes identical with Lpp up to
this point and apyrase can be considered as a fusion protein to
the first 22 amino acids of Lpp prolipoprotein. Interestingly,
both the LMAs have been retained in the inner membrane, as
judged from their solubilization by sarcosyl and the activity
seen in inverted vesicles.
The fact that both specificity (as judged from ATP hydro-
lysis, pyrophosphatase, peroxidase, catalase, chloroperoxidase
and phosphatase) (Madan Babu et al., 2002) and specific activ-
ity were the same among the native and the lipid-modified
forms supports the general belief that lipid modification at the
N-terminal end as occurs in bacteria does not affect the folding
of the rest of the protein and therefore retains its function, when
still anchored to the membrane. It is inferred from our study
that N-terminal lipid modification does not affect function and
the same kind of lipid modification at the N-terminal end is
possible for other proteins, perhaps except those in which the
N-terminus might be important for its function.
In conclusion, employing a heterologous, secretory and
sensitive enzymatic protein, we have demonstrated that bacter-
ial lipid modification can be an effective strategy to introduce a
hydrophobic anchor at the N-terminal end without perturbing
the structure and function. Such a modification can be achieved
using E.coli by either fusing the lipoprotein signal sequence
or modifying an existing secretory non-lipoprotein signal
sequence to contain lipobox. These strategies can be employed
to lipid modify other commercially important hydrophilic pro-
teins to acquire the benefits of lipoproteins. Lipoprotein apyr-
ase can also be employed to understand the lipid modification
mechanism operative in bacteria, such as membrane localiza-
tion and lipobox variations.
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